ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor. The company was founded in 2009 and is headquartered in Vancouver, Canada.
Industry, Sector and Symbol:
Capitalization:- Market Cap: C$12.51 million
- Outstanding Shares: 29,096,000
Average Prices:- 50 Day Moving Avg: C$0.50
- 200 Day Moving Avg: C$2.13
- 52 Week Range: C$0.31 - C$4.60
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: C($0.20) per share
- Price / Book: -2.15
Profitability:- EBIDTA: ($14,170,000.00)
- Return on Assets: -205.43%
Misc:- Average Volume: 136,629 shs.
Frequently Asked Questions for ESSA Pharma (TSE:EPI)
What is ESSA Pharma's stock symbol?
ESSA Pharma trades on the Tornton Stock Exchange (TSX) under the ticker symbol "EPI."
When will ESSA Pharma make its next earnings announcement?
Who are some of ESSA Pharma's key competitors?
Some companies that are related to ESSA Pharma include Primero Mining Corp (P), Trimel Pharmaceuticals Corp. (ASP), Petrowest Corp (PRW), Enterprise Group (E), Strongco Corp (SQP), Candente Copper Corp (DNT), Karnalyte Resources (KRN), Touchstone Exploration (TXP), Zargon Oil and Gas Ltd (ZAR), Guestlogix (GXI), Bri-Chem Corp (BRY), Niko Resources (NKO), 2242749 Ontario Ltd (ARF), Aastra Technologies Limited (AAH), Abcourt Mines (ABI), Agellan Commercial Real Estate Invtmt TR (ACR.UN), AGF Management Limited (AGF.B) and Ainsworth Lumber Co. (ANS).
Who are ESSA Pharma's key executives?
ESSA Pharma's management team includes the folowing people:
- Richard M. Glickman LL.D., Chairman of the Board
- David Ross Parkinson M.D., President, Chief Executive Officer, Director
- David Wood, Chief Financial Officer
- Peter Virsik, Chief Operating Officer, Executive Vice President
- Raymond L. Andersen, Chief Technology Officer, Director
- Marianne D. Sadar, Chief Scientific Officer, Director
- Frank Perabo, Chief Medical Officer
- Franklin M. Berger, Director
- Scott Requadt J.D., Director
- Gary Sollis, Director
How do I buy ESSA Pharma stock?
Shares of ESSA Pharma and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is ESSA Pharma's stock price today?
One share of ESSA Pharma stock can currently be purchased for approximately C$0.43.
MarketBeat Community Rating for ESSA Pharma (TSE EPI)MarketBeat's community ratings are surveys of what our community members think about ESSA Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for ESSA Pharma (TSE:EPI) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for ESSA Pharma (TSE:EPI)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 8/2/2017 | Dawson James | Reiterated Rating | Buy | |  |
| 5/18/2017 | Bloom Burton | Reiterated Rating | Buy | | |
(Data available from 8/20/2015 forward)
Earnings History for ESSA Pharma (TSE:EPI)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for ESSA Pharma (TSE:EPI)Current Year EPS Consensus Estimate: $-0.35 EPS
Dividend History for ESSA Pharma (TSE:EPI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ESSA Pharma (TSE:EPI)Insider Trades by Quarter for ESSA Pharma (TSE:EPI)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/24/2015 | Robert Rieder | Director | Buy | 3,600 | C$9.00 | C$32,389.20 | |
| 8/31/2015 | Marianne Sadar | Director | Sell | 22,000 | C$7.60 | C$167,200.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for ESSA Pharma (TSE:EPI)
Latest Headlines for ESSA Pharma (TSE:EPI)
| Source: |
|
ESSA Pharma (EPI) Chart for Sunday, August, 20, 2017
